OMRON Viso: Licensed to reduce stroke and heart disease risk
High blood pressure (also known as hypertension) is the third-biggest risk factor for disease and disability in the UK – despite being one of the most preventable and treatable conditions. Around one in three adults have high blood pressure, costing the NHS £2.1bn each year and taking up 12% of all GP visits.
While self-monitoring at home could provide a solution, its adoption has been low in the UK and there are concerns about patient anxiety and contradictory evidence. Launched in 2021, the groundbreaking Viso remote monitoring platform from global health technology company OMRON helps clinicians manage a patient’s medication plan based on home blood pressure readings.
The system, licensed via OUI, is underpinned by an exclusive algorithm and marks a major development in the digital transformation of the NHS and improvements to patient outcomes.
The effectiveness of home blood pressure monitoring has been assessed by a team led by Professor Richard McManus of Oxford’s Nuffield Department of Primary Care Health Sciences. A research study found that patients who self-monitor and have their medication dosage adjusted using home blood pressure readings have significantly lower blood pressure than patients whose dosage is guided by clinic readings. This blood pressure reduction, if sustained, would be expected to reduce stroke risk by 20% and coronary heart disease risk by 10%.
Viso has been rolled out in over 150 NHS practices, saving significant GP time, eliminating up to a third of appointments for hypertension, and driving change in the treatment of high blood pressure for patients across the UK
A research study found that patients who self-monitor and have their medication dosage adjusted using home blood pressure readings have significantly lower blood pressure than patients whose dosage is guided by clinic readings.
OUI activities
- Project management
Case study categories
- Health Tech
